NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Study Summary

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

Conditions

Hereditary Angioedema

Interventions / Drugs

Biological NTLA-2002 Normal Saline IV Administration

View on ClinicalTrials.gov ↗

Sponsor

NTLA

Intellia Therapeutics

Gene Editing

D44/100

Study Details

Enrollment37 participants

Primary Completion—

Lead SponsorIntellia Therapeutics

Data Retrieved2026-04-11 04:23:01.073813+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.